Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty ...

REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated ...

Milestones Abound In First Quarter The first quarter was a busy three months for Kamada as it hit several milestones, including the launch of a new post-marketing research program aimed at generating ...

Cytogam® is contraindicated in individuals with a history of a prior severe reaction associated with the administration of this or other human immunoglobulin preparations.

DETROIT, MICHIGAN - June 6, 2025 (NEWMEDIAWIRE) - Cytomegalovirus (CMV) is a common virus that most adults are exposed to at some point in their lives, and over half of American adults have been ...

Kamada Ltd., a global biopharmaceutical company, is addressing this challenge head-on by increasing efforts to promote CYTOGAM, its CMV immune globulin, and launching a post-marketing research program ...

In 2021, Kamada acquired CYTOGAM from its previous owner, and in 2023 the company received approval from the U.S. Food and Drug Administration for the manufacturing of the product.